PathoQuest Announces New Appointments to Executive Leadership Team
Company adds experienced executives to support the continued growth of Biologics Genomic Service and Clinical Diagnostics businesses which utilize PathoQuest’s proprietary Next-Generation Sequencing (NGS) based testing solution. PARIS, FRANCE – July 10,...
PathoQuest announces enrollment of first patient in IDENTIFY, a prospective clinical study assessing the medico-economic benefit of iDTECT™ Blood for the diagnosis of bloodstream infection in immunocompromised patients
Pour la version en français de ce communiqué de presse : cliquez ici PARIS, FRANCE, May 22, 2018 – PathoQuest, a genomic expert for biologics testing and a leader in improving pathogen identification in clinical biological samples, today announced the...
Charles River Laboratories and PathoQuest Expand Strategic Biologics Partnership
Partnership Charles River will provide clients access to PathoQuest’s NGS-based testing solutions WILMINGTON, MA and PARIS, FRANCE, April 9, 2018 – Charles River Laboratories International, Inc. (NYSE: CRL) and PathoQuest today announced an expansion of...
PathoQuest and Mayo Clinic Enter into an Agreement to Conduct Study of iDTECT™ Blood in Patients with Febrile Neutropenia
Pour la version en français de ce communiqué de presse : cliquez ici PathoQuest, a life sciences leader focused on improving pathogen identification in biological samples, today announced that it will conduct research with Mayo Clinic to study the...
PathoQuest Announces Formation of Scientific Advisory Board
Members of the Scientific Advisory Board are recognized infectious diseases, microbiology and next-generation sequencing experts. The Scientific Advisory Board will advise PathoQuest in its Research and Development efforts in metagenomics applied to...
PathoQuest Collaborating with Memorial Sloan Kettering Cancer Center to study iDTECT™ Blood in patients with febrile neutropenia
Pour la version en français de ce communiqué de presse : cliquez ici PathoQuest, a life sciences leader focused on improving pathogen detection in biological samples, today announced that it has entered into an agreement with Memorial Sloan Kettering...
Proof-of-concept study published in Clinical Microbiology and Infection reports the benefit of PathoQuest NGS-based metagenomics test
Click here to view French version of this release PathoQuest, a biotechnology company spun out from Institut Pasteur, announced today the on-line publication of results from the PATHOQUEST-1 study. The full manuscript, titled "Untargeted next-generation...
Laboratoire CERBA and PATHOQUEST announce partnership making the iDTECT™ BLOOD test available for clinical use in the precision diagnosis of infectious diseases
Laboratoire CERBA and PATHOQUEST announced today the signing of a licensing agreement for the iDTECT™ Blood test for use in the precision diagnosis of infectious diseases. Click here to view French version of this release iDTECT™ Blood is a metagenomic test developed...
PathoQuest Achieves CE Mark for the iDTECT™ Blood Test
iDTECT™ Blood is the first NGS-based metagenomics test to be CE-IVD marked for the clinical identification of pathogens from blood samples Click here to view French version of this release PathoQuest, a biotechnology company spun out from Institut Pasteur, today...
PathoQuest Announces Appointments to Executive Leadership Team
Company adds experienced executives to accelerate innovation and growth of their proprietary next generation sequencing (NGS) based solutions for Viral Safety Testing and clinical diagnostic of blood-based infections. Click here to view French version of this release...